300347 泰格醫藥
按盤價 
61.220 -3.000 (-4.671%)
61.220 -3.000 (-4.671%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 3,250,444 | -3.21% | 6,603,120 | 7,384,039 | 7,085,471 | 5,213,538 | |
| 減：營業總成本 | 2,942,263 | 12.03% | 5,610,048 | 5,554,125 | 5,156,544 | 3,637,765 | |
| 其中:營業成本 | 2,272,466 | 12.21% | 4,361,107 | 4,535,511 | 4,277,008 | 2,942,883 | |
| 財務費用 | 63,282 | -492.85% | 38,067 | (108,324) | (158,124) | (216,363) | |
| 資產減值損失 | (4,295) | -49.02% | 1,255 | (29,725) | (2,416) | (12,915) | |
| 公允價值變動收益 | (89,644) | -8.90% | (501,688) | 352,771 | 535,857 | 1,815,390 | |
| 投資收益 | 233,001 | 229.36% | 166,642 | 338,175 | 102,751 | 312,283 | |
| 其中：對聯營企業和合營企業的投資收益 | 166,386 | 277.33% | 31,271 | 105,183 | 39,763 | 14,348 | |
| 營業利潤 | 444,258 | -35.34% | 664,419 | 2,486,941 | 2,582,399 | 3,696,967 | |
| 利潤總額 | 442,689 | -35.85% | 664,462 | 2,488,533 | 2,585,377 | 3,684,566 | |
| 減：所得稅費用 | 79,861 | -39.73% | 216,630 | 338,606 | 313,652 | 292,864 | |
| 淨利潤 | 362,828 | -34.93% | 447,831 | 2,149,927 | 2,271,725 | 3,391,702 | |
| 減：非控股權益 | (20,509) | -131.68% | 42,688 | 125,077 | 265,173 | 517,539 | |
| 股東淨利潤 | 383,337 | -22.22% | 405,143 | 2,024,850 | 2,006,552 | 2,874,163 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.450 | -21.05% | 0.470 | 2.340 | 2.320 | 3.310 | |
| 每股派息 (元) * | -- | -- | 0.300 | 0.568 | 0.550 | 0.500 | |
| 每股淨資產 (元) * | 23.837 | -0.71% | 23.898 | 24.102 | 22.447 | 20.774 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 11/09/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
